Tivic Health Systems demonstrated significant progress in its strategic transformation, advancing its biologic pharmaceutical pipeline and making strides in its lead candidate, entolimod, despite some manufacturing delays.

• Successfully licensed entolimod, expanding the portfolio into biologic pharmaceuticals with a focus on immune system therapies.
• Initiated the transfer of INDs for entolimod, enabling swift potential entry into Phase II clinical studies for multiple indications, including acute radiation syndrome.
• Verified production of entolimod proteins, marking a key milestone in advancing towards CGMP compliance for regulatory submissions.
• Completed a VNS optimization study revealing surprising capabilities, suggesting potential reassessment of commercial strategies.
• Active engagement with BARDA and military stakeholders to explore entolimod's application as a countermeasure for ARS and potential stockpiling.